Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma.
Jonathan W. Friedberg(University of Rochester), Christopher A. Yasenchak(Willamette Valley Cancer Institute and Research Center), Andres Forero‐Torres(Kirklin Clinic), Jeff P. Sharman(Willamette Valley Cancer Institute and Research Center), Vivian Jean M. Cline(Texas Oncology), Jerome H. Goldschmidt, Robert W. Chen, Rodolfo Bordoni(Georgia Cancer Specialists), Dipti Patel‐Donnelly(Orthopaedic Research of Virginia), Beata Holkova(Virginia Commonwealth University), Yinghui Wang(Beijing Tongren Hospital), Ralph V. Boccia(Center for Cancer and Blood Disorders), Faith Galderisi(Atara Biotherapeutics (United States)), Gregg A. Olsen(Providence Saint Joseph Medical Center), Patrick J. Flynn(American Society of Clinical Oncology)
Cited by 4
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer
|Journal of Clinical Oncology|2004|1.5k